Trial Profile
A Randomized, Double-Blind, Placebo- and Oxycodone Immediate Release (IR)-Controlled Study of Tapentadol IR for the Treatment of Acute Pain Caused by Vertebral Compression Fractures Associated With Osteoporosis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Tapentadol (Primary) ; Oxycodone
- Indications Osteoporotic pain
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Pharmaceuticals; Johnson & Johnson Innovative Medicine
- 14 Apr 2010 Actual number of patients (108) added as reported by ClinicalTrials.gov.
- 14 Apr 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 12 Feb 2010 Status changed from recruiting to not yet recruiting as reported by ClinicalTrials.gov.